论文部分内容阅读
乳腺癌是发生在人体乳腺腺上皮组织的恶性肿瘤。男女比例分别占1%和99%,其中40至60岁及绝经期前后的妇女发病率比较高。依据癌细胞的转移程度,乳腺癌临床分期包括:0期、Ⅰ期、Ⅱ期、Ⅲ期和Ⅳ期。为阻断乳腺肿瘤细胞增殖,FDA授予辉瑞突破性乳腺癌新药Ibrance优先审查资格。除此之外,2017年3月23日,礼来公司也宣布临床上应用Abemaciclib治疗乳腺癌Ⅲ期迎来喜讯。同属CDK4/6抑制剂众所周知,细胞周期失控是癌症标志性特征之一。CDK4/6是细胞周期的关键调节因子,由于CDK4/6在许多癌症中均过度
Breast cancer is a malignant tumor that occurs in the human mammary gland epithelium. The male-female ratio accounted for 1% and 99% respectively, of which women aged 40 to 60 and pre-menopausal had a higher incidence. According to the degree of cancer metastasis, clinical stage of breast cancer include: 0, Ⅰ, Ⅱ, Ⅲ and Ⅳ. In order to block the proliferation of breast tumor cells, FDA granted Pfizer a breakthrough in breast cancer drug Ibrance priority review. In addition, on March 23, 2017, Eli Lilly and Company also announced that the clinical application of Abemaciclib for breast cancer III ushered in good news. It is well-known that CDK4 / 6 inhibitors belong to the same family, and cell cycle out of control is one of the hallmarks of cancer. CDK4 / 6 is a key regulator of the cell cycle, as CDK4 / 6 is over-represented in many cancers